Trashing cancer’s ‘undruggable’ proteins
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 11:16 ET (22-Jun-2026 15:16 GMT/UTC)
‘Undruggable' cancer-driving proteins resist various treatments because drugs cannot bind to them. New Velcro-like polymer grabs proteins without needing a traditional binding pocket. Polymers also grab the cell’s waste-disposal machinery, bringing it to the protein. Strategy worked in cellular cultures and animal models of cancer for two notoriously undruggable proteins.
Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, a new study finds.
St. Jude Children’s Research Hospital scientists found that hearing loss as a side effect of radiation therapy can increase the risk of cognitive decline.
Scientists have developed an adaptable materials platform that can safely and efficiently deliver a wide range of genetic medicines, a breakthrough that could accelerate the development of next‑generation vaccines, cancer treatments, and gene‑silencing drugs.
A Royal Orthopaedic Hospital NHS Foundation Trust (ROH) and Aston University collaboration has secured support to develop a minimally invasive anti-cancer and bone regenerative injectable paste, using the cancer-killing properties of gallium.
The team has secured a place on the SPARK THE MIDLANDS programme which aims to provide academic support to advance healthcare research discoveries in the region.
The team from the ROH includes Dr Lucas Souza, Professor Adrian Gardner, and Mr Jonathan Stevenson alongside Professor Richard Martin and Dr Eirini Theodosiou from Aston University. Together, they will use the SPARK programme to secure a route for the cancer-killing paste to be taken from the lab, into clinics and hospitals. If proved effective through clinical trials, the paste - a gallium-doped bioglass - could be used to treat patients with primary and metastatic bone cancer.